Research programme: herpes simplex virus type 2 vaccines - Shionogi
Alternative Names: HSV-2 vaccines - ShionogiLatest Information Update: 28 Jun 2024
At a glance
- Originator Shionogi
- Class Subunit vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Herpes simplex virus type 2 infections
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for research development in Herpes simplex virus type-2 infections(Prevention) in Japan (Parenteral)
- 19 May 2020 Genocea Biosciences and Shionogi collaborate to develop vaccine candidates for herpes simplex virus type 2 (HSV-2) infections
- 19 May 2020 Early research in Herpes simplex virus type 2 infections (Prevention) in Japan (Parenteral)